ISIN CH0210193584

As at 11 September 2025

UBS (CH) Suisse - 65 (CHF) Q-dist

Risk indicator (SRI)




Investment strategy

This sub-fund invests its assets primarily in the investments of issuers that have their head office in Switzerland or that exercise the bulk of their business activities in Switzerland, or, as holding companies, mainly have investments in companies domiciled in Switzerland or in investments denominated in Swiss francs (CHF).

Master data

Fund management company	UBS Fund Manage- ment (Switzerland) AG		
Fund domicile	Switzerland		
Inception date	27 November 2015		
ISIN	CH0210193584		
Swiss security no.	21019358		
Fund currency	CHF		
Appropriation of income	distributing		
Ongoing charges under PRIIP KID as at 11 February 2021	1.07%		
End of financial year	31 August		
Paying agent	UBS Switzerland AG		
Fund volume as at 30 November 2021	CHF 358.80m		
Net asset value (NAV) as at 11 September 2025	139.71 CHF		

Performance (in CHF)



	2019	2020	2021	2022	2023	2024
Performance p. a.	19.41%	4.09%	13.56%	-16.13%	4.38%	6.83%

Source: fund management company

As at 11 September 2025

Fund performance

	YTD	1 year	3 years	5 years	10 years	since inception
Performance p. a. Cumulative performance	-	7.30%	4.99%	3.80%	-	4.13%
	7.14%	7.30%	15.74%	20.53%	-	48.60%
Volatility	9.29%	8.67%	8.03%	8.64%	-	9.45%

Source: fund management company

As at 11 September 2025

Top holdings of fund volume (in %)

1.	Nestle	6.68%
2.	Roche Hldg. Genußsch.	5.07%
3.	Novartis	3.23%
4.	RICHEMONT(CIE FIN) CHF1.00 (REG) SER 'A'	1.43%
5.	Zürich Versicherung	1.14%
Sou	rce: fund management company	As at 30 November 2021

Disclaimer: This is a marketing document. The statements herein are provided for information purposes only. They do not constitute an offer, investment advice or a recommendation to acquire or sell financial instruments or to conclude any other legal transactions. This document has been produced with the greatest possible care and to the best of our knowledge and belief. However, we provide no guarantee with regard to its content and completeness and do not accept any liability for losses which may arise from making use of this information. Past performance is not an indicator of current and future developments and results. The performance shown here has been calculated net of fees. It does not include any issuing commissions charged when purchases are made. The regulatory documentation for the collective investments contained in the portfolios (such as the prospectus, fund contract, key investor information document [KIID] or key information document and latest annual/half-year report) can be obtained free of charge in printed or electronic form from Swiss Life Asset Management Ltd , General-Guisan-Quai 40, 8002 Zurich, info@swisslife-am.com and from the applicable Swiss fund management and, for funds domiciled abroad, their respective representatives in Switzerland. You can obtain the ordering addresses and details of the fund management company, the representative, the payment office and the country of origin of the collective investment from Swiss Life Asset Management Ltd. The published information is intended exclusively for persons domiciled in Switzerland. The products and collective investments outlined here may not be acquired directly or indirectly by persons deemed to be US persons under US tax law or by persons who are subject to US tax law for any other reason, nor may they be transferred to them.